
Onkos Surgical, Inc. announced today that it has partnered with Promimic AB, the world’s leading innovator in nano surface modification, to commercialize Promimic’s proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery.
Onkos Surgical, Inc. announced today that it has partnered with Promimic AB, the world’s leading innovator in nano surface modification, to commercialize Promimic’s proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery.
9. Since its inception in October 2015, the company has already supported over 200 surgeons and over 1,100 limbs have been saved using Onkos products.
The Private Equity Women Investor Network (PEWIN), the pre-eminent organization for senior-level women investment professionals in private equity, today announced that its Members – Adele Oliva (1315 Capital), Hollie Haynes (Luminate Capital Partners), Kristina Heinze (ParkerGale) and Kate Mitchell (Scale Venture Partners) – have each successfully closed a new fund.
Onkos Surgical, Inc. announced today that it has launched MyTray, a fully integrated personal surgical planning solution that leverages preoperative imaging and the precision of surgeon specific procedural requirements; all delivered in the convenience of personalized instrumentation trays. The MyTray solution is powered by the company’s novel digital health platform called uDesign™.
Colorescience® announces the launch of PEP UP™ Collagen Renewal Face & Neck Treatment, a powerful clinically-tested treatment that trains skin to build its own healthy collagen to defend against the visible signs of aging.
Colorescience®, leading dermatologist-recommended skincare and cosmetics company, is proud to introduce its latest innovation, the Colorescience Total Eye™ Restore Regimen, a comprehensive, 24-hour solution that immediately addresses multiple eye area concerns and provides long-term improvement.
The announcement was made today, at the 15th annual Maui Derm Conference, that Impoyz Cream demonstrated efficacy early, with 14.2% of Impoyz patients achieving treatment success at day 8 versus 1.6% in the vehicle group. Treatment success was achieved when subjects received a “clear” or “almost clear” assessment, marking at least a 2-grade improvement from …
Biocoat, Inc. announced today that Steven Bell has joined the company as Chief Financial Officer (CFO). Based in Horsham, PA, Biocoat develops and licenses biomaterial coatings for interventional medical devices that are custom engineered to meet specific clinical design parameters.
Biocoat, Inc., (Biocoat) a 27-year old privately held company, announced today that it has been acquired by 1315 Capital, a Philadelphia-based healthcare investment firm that provides expansion and growth capital to commercial-stage healthcare services, medical technology, and specialty pharmaceutical companies.
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of the parent company of Genoptix, Inc. for $125 million in cash, as adjusted by working capital and other adjustments, and 1 million shares of NeoGenomics common stock. Genoptix is a leading clinical oncology laboratory, …
Encore Dermatology, Inc. today announced the publication of a Phase 2, open-label study in SKIN The Journal of Cutaneous Medicine. Subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temovate® (clobetasol propionate) Cream, 0.05% (56.3 vs 152.5 pg/mL, P=0.014).
Innovative Health, a national leader in medical device reprocessing for the cardiology sector, announced it has received FDA clearances to reprocess the Advisor FL Circular Mapping Catheter, Medtronic’s Torqr™ and Marinr™, and Biosense Webster’s DECANAV. Three of these clearances were received within the last month alone.